### Drug Therapy Protocols: Metaraminol

<table>
<thead>
<tr>
<th>Policy code</th>
<th>DTP_META_0120</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>January, 2020</td>
</tr>
<tr>
<td>Purpose</td>
<td>To ensure a consistent procedural approach to metaraminol administration.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to all Queensland Ambulance Service (QAS) clinical staff.</td>
</tr>
<tr>
<td>Health care setting</td>
<td>Pre-hospital assessment and treatment.</td>
</tr>
<tr>
<td>Population</td>
<td>Applies to all ages unless specifically mentioned.</td>
</tr>
<tr>
<td>Source of funding</td>
<td>Internal – 100%</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>January, 2023</td>
</tr>
</tbody>
</table>

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

### Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.


This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en](http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en)

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au
Metaraminol

Drug class
Sympathomimetic amine

Pharmacology
Metaraminol causes release of accumulated noradrenaline from nerve endings which then acts to increase systolic and diastolic blood pressure by directly and indirectly stimulating the alpha receptors in the sympathetic nervous system. This alpha stimulation causes vasoconstriction of the blood vessels. It also has a positive inotropic effect on the heart.[1,2]

Metabolism
Hepatic.[1]

Precautions
- Ischaemic heart disease
- Thyroid disease
- Hypertension
- Diabetes

Side effects
- Tissue necrosis if extravasation occurs
- Reduced blood flow to ‘non vital’ (skin and gut) organs

Indications
- Hypotension (without hypovolaemia)
- Prevention and treatment of the acute hypotensive state occurring with anaesthesia

Contraindications
- Allergy and/or Adverse Drug Reaction
- Current MAOI therapy
- Pregnancy
- Hypovolaemia secondary to ongoing haemorrhage

Presentation
- Ampoule, 3 mg/6 mL metaraminol

Onset (IV) | Duration (IV) | Half-life
--- | --- | ---
1–2 minutes | up to 20 minutes | Minutes
**Special notes**

- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the QAS Clinical Consult and Advice Line.
- Rapid excessive hypertension may precipitate APO, cardiac arrhythmias, cerebral haemorrhage or cardiac arrest.
- All cannulae/EZ-IO® and IV lines must be flushed thoroughly with sodium chloride 0.9% following each medication administration.

**Routes of administration**

- Intravenous injection (IV)
- Intraosseous injection (IO)

**Schedule**

- S4 (Restricted drugs).

**Adult dosages**

- **Hypotension** (without hypovolaemia)
- **Prevention and treatment of the acute hypotensive state occurring with anaesthesia**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Administration</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV/IO</td>
<td>0.5 mg</td>
<td>Repeated at 1 minute intervals. No maximum dose.</td>
<td></td>
</tr>
</tbody>
</table>

**Paediatric dosages**

**Note:** QAS officers are NOT authorised to administer metaraminol to paediatric patients.